Advanced

Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement

Albanese, Alberto; Abbruzzese, Giovanni; Dressler, Dirk; Duzynski, Wojciech LU ; Khatkova, Svetlana; Jose Marti, Maria; Mir, Pablo; Montecucco, Cesare; Moro, Elena and Pinter, Michaela, et al. (2015) In Journal of Neurology 262(10). p.2201-2213
Abstract
Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients' self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group... (More)
Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients' self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dystonia, Torticollis, Botulinum toxins, Botulinum toxin type A, Decision making, Consensus development conference
in
Journal of Neurology
volume
262
issue
10
pages
2201 - 2213
publisher
Steinkopff
external identifiers
  • wos:000363035800001
  • scopus:84944511294
ISSN
1432-1459
DOI
10.1007/s00415-015-7703-x
language
English
LU publication?
yes
id
7b36d67b-0e81-4792-b425-ed611e28a2c2 (old id 8198654)
date added to LUP
2015-12-01 07:07:52
date last changed
2017-10-01 04:00:17
@article{7b36d67b-0e81-4792-b425-ed611e28a2c2,
  abstract     = {Cervical dystonia is a neurological movement disorder causing abnormal posture of the head. It may be accompanied by involuntary movements which are sometimes tremulous. The condition has marked effects on patients' self-image, and adversely affects quality of life, social relationships and employment. Botulinum neurotoxin (BoNT) is the treatment of choice for CD and its efficacy and safety have been extensively studied in clinical trials. However, current guidelines do not provide enough practical information for physicians who wish to use this valuable treatment in a real-life setting. In addition, patients and physicians may have different perceptions of what successful treatment outcomes should be. Consequently, an international group of expert neurologists, experienced in BoNT treatment, met to review the literature and pool their extensive clinical experience to give practical guidance about treatment of CD with BoNT. Eight topic headings were considered: the place of BoNT within CD treatment options; patient perspectives and desires for treatment; assessment and goal setting; starting treatment with BoNT-A; follow-up sessions; management of side effects; management of non-response; switching between different BoNT products. One rapporteur took responsibility for summarising the current literature for each topic, while the consensus statements were developed by the entire expert group. These statements are presented here along with a discussion of the background information.},
  author       = {Albanese, Alberto and Abbruzzese, Giovanni and Dressler, Dirk and Duzynski, Wojciech and Khatkova, Svetlana and Jose Marti, Maria and Mir, Pablo and Montecucco, Cesare and Moro, Elena and Pinter, Michaela and Relja, Maja and Roze, Emmanuel and Skogseid, Inger Marie and Timerbaeva, Sofiya and Tzoulis, Charalampos},
  issn         = {1432-1459},
  keyword      = {Dystonia,Torticollis,Botulinum toxins,Botulinum toxin type A,Decision making,Consensus development conference},
  language     = {eng},
  number       = {10},
  pages        = {2201--2213},
  publisher    = {Steinkopff},
  series       = {Journal of Neurology},
  title        = {Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement},
  url          = {http://dx.doi.org/10.1007/s00415-015-7703-x},
  volume       = {262},
  year         = {2015},
}